Five Takeaways from the Second Circuit’s Namenda Decision
July 24, 2015
The Second Circuit's recent decision in New York v. Actavis, a case concerning the Alzheimer’s Disease treatment Namenda, grabbed headlines as the first appellate decision to uphold an injunction barring a branded pharmaceutical manufacturer from pulling a patented drug from the market. Now that the dust has settled after the ruling, it is time to assess how the decision could impact antitrust law inside and outside of the pharmaceutical industry.
COPYRIGHT © 2015 BY THE BUREAU OF NATIONAL AFFAIRS, INC. ISSN
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.